已收录 268921 条政策
 政策提纲
  • 暂无提纲
COVID-19 Disease and Dermatomyositis: A Mini-Review
[摘要] The pandemic of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has caused a large number of deaths, and there is still no effective treatment. COVID-19 can induce a systemic inflammatory response, and its clinical manifestations are diverse. Recently, it has been reported that COVID-19 patients may develop myositis and interstitial pulmonary disease similar to dermatomyositis (DM). This condition is similar to the rapidly progressive interstitial lung disease associated with MDA5+ DM that has a poor prognosis and high mortality, and this poses a challenge for an early identification. Suppression of the immune system can protect COVID-19 patients by preventing the production of inflammatory cytokines. This article attempts to explore the possibility of a relationship between COVID-19 and DM in terms of the potential pathogenesis and clinical features and to analyze the therapeutic effect of the immunosuppressive drugs that are commonly used for the treatment of both DM and COVID-19.
[发布日期] 2022-01-13 [发布机构] 
[效力级别]  [学科分类] 
[关键词] SARS-CoV-2;COVID-19;dermatomyositis;pathogenesis;treatment [时效性] 
   浏览次数:1      统一登录查看全文      激活码登录查看全文